[go: up one dir, main page]

MXPA03008032A - Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida. - Google Patents

Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.

Info

Publication number
MXPA03008032A
MXPA03008032A MXPA03008032A MXPA03008032A MXPA03008032A MX PA03008032 A MXPA03008032 A MX PA03008032A MX PA03008032 A MXPA03008032 A MX PA03008032A MX PA03008032 A MXPA03008032 A MX PA03008032A MX PA03008032 A MXPA03008032 A MX PA03008032A
Authority
MX
Mexico
Prior art keywords
csf
stimulating factor
colony stimulating
macrophage colony
granulocyte macrophage
Prior art date
Application number
MXPA03008032A
Other languages
English (en)
Inventor
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA03008032A publication Critical patent/MXPA03008032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MXPA03008032A 2001-03-08 2002-02-28 Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida. MXPA03008032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105775 2001-03-08
PCT/EP2002/002148 WO2002070548A2 (en) 2001-03-08 2002-02-28 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity

Publications (1)

Publication Number Publication Date
MXPA03008032A true MXPA03008032A (es) 2003-12-04

Family

ID=8176721

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008032A MXPA03008032A (es) 2001-03-08 2002-02-28 Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.

Country Status (15)

Country Link
US (1) US7208147B2 (es)
EP (1) EP1366074B1 (es)
JP (1) JP2004535777A (es)
KR (1) KR20030082962A (es)
CN (1) CN1494551A (es)
AT (1) ATE339446T1 (es)
BR (1) BR0207945A (es)
CA (1) CA2439926A1 (es)
DE (1) DE60214682T2 (es)
HU (1) HUP0303429A3 (es)
MX (1) MXPA03008032A (es)
PL (1) PL362986A1 (es)
RU (1) RU2003129058A (es)
WO (1) WO2002070548A2 (es)
ZA (1) ZA200307829B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
ES2609088T3 (es) 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
SG10201709849TA (en) 2011-11-29 2017-12-28 Proclara Biosciences Inc Use of p3 of bacteriophage as amyloid binding agents
LT2906235T (lt) 2012-10-02 2017-10-25 Proclara Biosciences, Inc. Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
US9988444B2 (en) 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
CA2342967A1 (en) * 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity

Also Published As

Publication number Publication date
US20040092717A1 (en) 2004-05-13
EP1366074B1 (en) 2006-09-13
DE60214682T2 (de) 2007-09-13
HUP0303429A3 (en) 2005-12-28
PL362986A1 (en) 2004-11-15
JP2004535777A (ja) 2004-12-02
WO2002070548A2 (en) 2002-09-12
ZA200307829B (en) 2004-07-21
KR20030082962A (ko) 2003-10-23
EP1366074A2 (en) 2003-12-03
RU2003129058A (ru) 2005-04-20
ATE339446T1 (de) 2006-10-15
CN1494551A (zh) 2004-05-05
CA2439926A1 (en) 2002-09-12
HUP0303429A2 (hu) 2004-01-28
DE60214682D1 (de) 2006-10-26
BR0207945A (pt) 2004-07-27
WO2002070548A3 (en) 2003-05-01
US7208147B2 (en) 2007-04-24

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
MXPA03008032A (es) Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
IL212076A (en) Isolated polypeptides of ifn – a method for their preparation, medicinal preparations containing them and their use in the preparation of drugs for treatment with interferon
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
HUP0401534A2 (hu) Módosított humán IX. faktor
WO2006010143A3 (en) Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
WO2002077034A3 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
HUP0303310A2 (hu) Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
MXPA04000339A (es) MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS.
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
ATE515258T1 (de) Mukosales verabreichungssytem
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
DK1173476T3 (da) Funktionelle sojabönneproteiner
WO2020226854A3 (en) Tolerogenic artificial antigen-presenting cells
WO2002074808A3 (en) Modified insulin with reduced immunogenicity